{"title":"Gastrointestinal microbiota in treatment of gastric precancerous lesions and gastric cancer by Western and traditional Chinese medicine.","authors":"Ting-Lan Cao, Hui-Zhong Jiang","doi":"10.5306/wjco.v16.i8.107660","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric precancerous lesions (GPL) represent a crucial stage in the complex process of gastric carcinogenesis that leads to gastric cancer (GC), one of the most prevalent cancers and a major source of cancer mortality worldwide. Many studies have identified the gastrointestinal microbiota, or gut microbiota, as an important contributor to both the pathogenesis and treatment of GPL and GC, thus understanding its role in this transition is crucial. The purpose of this literature review is to introduce the current landscape of microbiota research associated with GPL and GC, with an emphasis on <i>Helicobacter pylori</i> (<i>H. pylori</i>) driven microbial dysbiosis and its modulation through Western medicine and traditional Chinese medicine (TCM) approaches. By elucidating the underlying mechanisms of <i>H. pylori</i> colonization, patterns, and interactions among microbiota, as well as the influence of microbial metabolites, this review highlights crucial driving factors of gastric carcinogenesis. The role of microbiota in conventional interventions, including <i>H. pylori</i> eradication, immunotherapy, as well as TCM herbal decoctions, is also discussed to provide a detailed understanding of the complex interactions between therapy and microbiota and how it could be potentially targeted for effective management of GPL and GC. Ultimately, microbiota-targeting therapeutics may represent a new path toward early detection, targeted treatment, improved prognosis, and potentially reduced incidence of GPL and GC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"107660"},"PeriodicalIF":3.2000,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400207/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i8.107660","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Gastric precancerous lesions (GPL) represent a crucial stage in the complex process of gastric carcinogenesis that leads to gastric cancer (GC), one of the most prevalent cancers and a major source of cancer mortality worldwide. Many studies have identified the gastrointestinal microbiota, or gut microbiota, as an important contributor to both the pathogenesis and treatment of GPL and GC, thus understanding its role in this transition is crucial. The purpose of this literature review is to introduce the current landscape of microbiota research associated with GPL and GC, with an emphasis on Helicobacter pylori (H. pylori) driven microbial dysbiosis and its modulation through Western medicine and traditional Chinese medicine (TCM) approaches. By elucidating the underlying mechanisms of H. pylori colonization, patterns, and interactions among microbiota, as well as the influence of microbial metabolites, this review highlights crucial driving factors of gastric carcinogenesis. The role of microbiota in conventional interventions, including H. pylori eradication, immunotherapy, as well as TCM herbal decoctions, is also discussed to provide a detailed understanding of the complex interactions between therapy and microbiota and how it could be potentially targeted for effective management of GPL and GC. Ultimately, microbiota-targeting therapeutics may represent a new path toward early detection, targeted treatment, improved prognosis, and potentially reduced incidence of GPL and GC.
期刊介绍:
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.